Kimberly Cooper
About
Kimberly Cooper is a scholar working on Pharmacology, Biological Psychiatry and Experimental and Cognitive Psychology.
According to data from OpenAlex, Kimberly Cooper has authored 25 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 6 papers in Biological Psychiatry and 6 papers in Experimental and Cognitive Psychology. Recurrent topics in Kimberly Cooper's work include Treatment of Major Depression (11 papers), Tryptophan and brain disorders (6 papers) and Attention Deficit Hyperactivity Disorder (5 papers). Kimberly Cooper is often cited by papers focused on Treatment of Major Depression (11 papers), Tryptophan and brain disorders (6 papers) and Attention Deficit Hyperactivity Disorder (5 papers). Kimberly Cooper collaborates with scholars based in United States, Belgium and Germany. Kimberly Cooper's co-authors include Ella Daly, Wayne C. Drevets, Jaskaran Singh, Husseini K. Manji, Pilar Lim, Michael E. Thase, Maggie Fedgchin, Luc Van Nueten, Richard C. Shelton and Andrew Winokur and has published in prestigious journals such as American Journal of Psychiatry, Journal of Consulting and Clinical Psychology and Biological Psychiatry.
In The Last Decade
Kimberly Cooper
24 papers receiving 1.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Kimberly Cooper United States | 14 | 1.2k | 869 | 466 | 388 | 345 | 25 | 1.9k | ||
| Sarah Pillemer United States | 10 | 1.3k 1.0× | 1.0k 1.2× | 469 1.0× | 420 1.1× | 280 0.8× | 13 | 1.9k | ||
| Rayan K. Al Jurdi United States | 15 | 1.1k 0.9× | 962 1.1× | 622 1.3× | 348 0.9× | 260 0.8× | 21 | 1.9k | ||
| Laili Soleimani United States | 16 | 798 0.6× | 690 0.8× | 308 0.7× | 315 0.8× | 203 0.6× | 35 | 1.3k | ||
| P. Šóš Czechia | 14 | 808 0.6× | 499 0.6× | 281 0.6× | 212 0.5× | 336 1.0× | 32 | 1.4k | ||
| Syed Iqbal United States | 7 | 947 0.8× | 789 0.9× | 215 0.5× | 283 0.7× | 205 0.6× | 15 | 1.2k | ||
| David Christmas United Kingdom | 21 | 591 0.5× | 333 0.4× | 608 1.3× | 257 0.7× | 514 1.5× | 39 | 2.3k | ||
| Tom K. Birkenhäger Netherlands | 25 | 1.1k 0.9× | 513 0.6× | 1.3k 2.7× | 138 0.4× | 201 0.6× | 89 | 2.1k | ||
| Christina Kurre Olsen Denmark | 14 | 793 0.6× | 316 0.4× | 330 0.7× | 287 0.7× | 372 1.1× | 25 | 1.4k | ||
| Abhishekh H. Ashok United Kingdom | 19 | 381 0.3× | 410 0.5× | 461 1.0× | 614 1.6× | 124 0.4× | 42 | 1.8k | ||
| Ioana Florea Denmark | 22 | 941 0.8× | 281 0.3× | 389 0.8× | 127 0.3× | 648 1.9× | 41 | 1.3k |
Countries citing papers authored by Kimberly Cooper
Since
Specialization
Citations
This map shows the geographic impact of Kimberly Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly Cooper more than expected).
Fields of papers citing papers by Kimberly Cooper
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kimberly Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly Cooper. The network helps show where Kimberly Cooper may publish in the future.
Co-authorship network of co-authors of Kimberly Cooper
This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly Cooper. A scholar is included among the top collaborators of Kimberly Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly Cooper. Kimberly Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jamieson, Carol, Vanina Popova, Ella Daly, et al.. (2023). Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant. Health and Quality of Life Outcomes. 21(1). 40–40.
2.
Floden, Lysbeth, Stacie Hudgens, Carol Jamieson, et al.. (2022). Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant. CNS Drugs. 36(6). 649–658.
3.
Freeman, Marlene P., Susan G. Kornstein, Kimberly Cooper, et al.. (2022). Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. Archives of Women s Mental Health. 25(2). 313–326.
4.
Hudgens, Stacie, Lysbeth Floden, Carol Jamieson, et al.. (2020). Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant. Journal of Affective Disorders. 281. 767–775.
5.
Hudgens, Stacie, Lysbeth Floden, Carol Jamieson, et al.. (2020). 175 Determining Meaningful Change in Depression Symptoms Assessed with PHQ-9 and SDS in Treatment-resistant Depression Trials of Esketamine Nasal Spray. CNS Spectrums. 25(2). 311–312.
6.
Popova, Vanina, Ella Daly, Madhukar H. Trivedi, et al.. (2019). Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. American Journal of Psychiatry. 176(6). 428–438.
7.
Popova, Vanina, Ella Daly, Madhukar H. Trivedi, et al.. (2018). S111. Randomized, Double-Blind Study of Flexibly-Dosed Intranasal Esketamine Plus Oral Antidepressant Vs. Active Control in Treatment-Resistant Depression. Biological Psychiatry. 83(9). S390–S390.
8.
Daly, Ella, Jaskaran Singh, Maggie Fedgchin, et al.. (2017). Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression. JAMA Psychiatry. 75(2). 139–139.
9.
Schwartz, Sherwyn, Mila Etropolski, Douglas Y. Shapiro, et al.. (2014). A Pooled Analysis Evaluating the Efficacy and Tolerability of Tapentadol Extended Release for Chronic, Painful Diabetic Peripheral Neuropathy. Clinical Drug Investigation. 35(2). 95–108.
10.
Weisler, Richard H., Gahan Pandina, Ella Daly, Kimberly Cooper, & Cristiana Gassmann-Mayer. (2012). Randomized Clinical Study of a Histamine H3 Receptor Antagonist for the Treatment of Adults with Attention-Deficit Hyperactivity Disorder. CNS Drugs. 26(5). 421–434.
11.
Cooper, Kimberly, et al.. (2011). A Randomized, Placebo-controlled Trial of Acetaminophen Extended Release for Treatment of Post-marathon Muscle Soreness. Clinical Journal of Pain. 28(3). 204–210.
12.
Newcorn, Jeffrey H., Mark A. Stein, & Kimberly Cooper. (2010). Dose–Response Characteristics in Adolescents with Attention-Deficit/Hyperactivity Disorder Treated with OROS ® Methylphenidate in a 4-Week, Open-Label, Dose-Titration Study. Journal of Child and Adolescent Psychopharmacology. 20(3). 187–196.
13.
Adler, Lenard A., Camille Orman, H. Lynn Starr, et al.. (2010). Long-Term Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. 31(1). 108–114.
14.
Schnitzer, Thomas J., John Tesser, Kimberly Cooper, & Roy D. Altman. (2008). A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis. Osteoarthritis and Cartilage. 17(1). 1–7.
15.
Spencer, Thomas, Stephen V. Faraone, Marc Lerner, Kimberly Cooper, & Brenda Zimmerman. (2007). EFFECT OF LONG-TERM TREATMENT WITH STIMULANT MEDICATION ON GROWTH?. Journal of the American Academy of Child & Adolescent Psychiatry. 46(3). 306–306.
16.
Hanauer, Stephen B., Herbert L. DuPont, Kimberly Cooper, & Charles Laudadio. (2007). Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Current Medical Research and Opinion. 23(5). 1033–1043.
17.
Spencer, Thomas, Stephen V. Faraone, Joseph Biederman, et al.. (2006). Does Prolonged Therapy With a Long-Acting Stimulant Suppress Growth in Children With ADHD?. Journal of the American Academy of Child & Adolescent Psychiatry. 45(5). 527–537.
18.
Kuffner, Edwin K., Anthony R. Temple, Kimberly Cooper, Jeffrey S. Baggish, & Dennis Parenti. (2006). Retrospective analysis of transient elevations in alanine aminotransferase during long-term treatment with acetaminophen in osteoarthritis clinical trials. Current Medical Research and Opinion. 22(11). 2137–2148.
19.
Cooper, Kimberly, et al.. (2004). Acetaminophen Availability Increases in Canada with No Increase in the Incidence of Reports of Inpatient Hospitalizations with Acetaminophen Overdose and Acute Liver Toxicity. American Journal of Therapeutics. 11(6). 443–452.
20.
Borkovec, Thomas D., Jonathan B. Grayson, & Kimberly Cooper. (1978). Treatment of general tension: Subjective and physiological effects of progressive relaxation.. Journal of Consulting and Clinical Psychology. 46(3). 518–528.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sarah Pillemer Breakdown of academic impact, for papers by Rayan K. Al Jurdi Breakdown of academic impact, for papers by Laili Soleimani Breakdown of academic impact, for papers by P. Šóš Breakdown of academic impact, for papers by Syed Iqbal Breakdown of academic impact, for papers by David Christmas Breakdown of academic impact, for papers by Tom K. Birkenhäger Breakdown of academic impact, for papers by Christina Kurre Olsen Breakdown of academic impact, for papers by Abhishekh H. Ashok Breakdown of academic impact, for papers by Ioana Florea